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Urine-NMR metabolomics for 
screening of advanced colorectal 
adenoma and early stage colorectal 
cancer
eun Ran Kim1, Hyuk Nam Kwon2,3, Hoonsik Nam  2, Jae J. Kim1, sunghyouk park2 & 
Young-Ho Kim1
Although colorectal cancer (CRC) is considered one of the most preventable cancers, no non-invasive, 
accurate diagnostic tool to screen CRC exists. We explored the potential of urine nuclear magnetic 
resonance (NMR) metabolomics as a diagnostic tool for early detection of CRC, focusing on advanced 
adenoma and stage 0 CRC. Urine metabolomics profiles from patients with colorectal neoplasia (CRN; 
36 advanced adenomas and 56 CRCs at various stages, n = 92) and healthy controls (normal, n = 156) 
were analyzed by NMR spectroscopy. Healthy and CRN groups were statistically discriminated using 
orthogonal projections to latent structure discriminant analysis (opLs-DA). the class prediction model 
was validated by three-fold cross-validation. The advanced adenoma and stage 0 CRC were grouped 
together as pre-invasive CRN. The OPLS-DA score plot showed statistically significant discrimination 
between pre-invasive CRN as well as advanced CRC and healthy controls with a Q2 value of 0.746. In 
the prediction validation study, the sensitivity and specificity for diagnosing pre-invasive CRN were 
96.2% and 95%, respectively. The grades predicted by the OPLS-DA model showed that the areas 
under the curve were 0.823 for taurine, 0.783 for alanine, and 0.842 for 3-aminoisobutyrate. In multiple 
receiver operating characteristics curve analyses, taurine, alanine, and 3-aminoisobutyrate were good 
discriminators for CRC patients. NMR-based urine metabolomics profiles significantly and accurately 
discriminate patients with pre-invasive CRN as well as advanced CRC from healthy individuals. Urine-
NMR metabolomics has potential as a screening tool for accurate diagnosis of pre-invasive CRN.
Colorectal Cancer (CRC) is one of the most common causes of cancer-related deaths globally. The incidence of 
CRC is expected to exceed 2 million new cases by 2030, resulting in more than 1 million deaths. Rapid increases 
in CRC incidence and mortality have been described in many low/middle-income countries1,2. CRC development 
is characterized by very slow progression from adenoma to carcinoma due to the accumulation of various genetic 
and epigenetic mutations over decades3. A large proportion of CRC cases and deaths could be prevented by 
screening and early detection and removal of colorectal adenomas or early stage CRC4,5. Therefore, the develop-
ment of reliable and non-invasive screening tools for early stage CRC and precancerous lesions, such as adenoma, 
is indispensable.
Colonoscopic screening and surveillance have a well-documented benefit in reducing the risk of CRC by 
direct removal of precancerous lesion and early detection of CRC6,7. However, the use of colonoscopy as a screen-
ing tool is limited because it is an invasive and unpleasant procedure that necessitates bowel preparation and 
sedation. Instead, the fecal occult blood test (FOBT) has been commonly used in the clinic. An unacceptably wide 
range or the lack of sensitivity and specificity of the FOBT has hampered its clinical application in CRC diagnosis, 
especially for precancerous lesions8. Tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate 
antigen 19-9 (CA 19-9) are also commonly used in the clinic. However, these tumor markers cannot be used 
alone to screen for or diagnose CRC because their sensitivity is low. Blood levels of these components may rise 
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due to benign diseases such as inflammatory bowel disease and pneumonia, and even in smokers. Thus, there 
are no non-invasive screening tools for detecting precancerous lesions, such as colorectal adenoma. Recently, 
endoscopic resection (ER) has been established as the therapeutic option for early CRC with no risk of lymph 
node metastasis9. Compared with surgery, ER advantages include reduced invasiveness, shorter hospital stay, and 
lower costs10. Therefore, the development of a low-cost, easy, and accurate diagnostic approach for the detection 
of advanced adenoma and early stage CRC would be essential for complete recovery of the patient and to reduce 
medical expenses.
Metabolomics is one of the emerging ‘omics’ studies used to investigate global or system-wide metabolic pro-
files. It provides a dynamic portrait of the metabolic status of living systems11. This approach has great potential in 
the diagnosis of various cancers using advanced analytic techniques and bioinformatics tools12, it has already been 
used for therapeutic monitoring and drug development13,14. A few metabolic markers are consistently found in 
CRC, but metabolic profiles of patients with early stage CRC including precancerous lesions remain poorly under-
stood and warrant further investigation due to the non-invasive nature of the approach15,16. In the last decade, 
several metabolomics approaches were used to identify metabolic alterations in CRC using a variety of sample 
types including urine, tissue, serum and feces17, but only a few urinary metabolomics studies were published18–21. 
Nuclear magnetic resonance (NMR) spectroscopy is one of the major analytical techniques used in metabolomics 
research; it has several advantages including a relatively high degree of reproducibility, easy-to-identify metabo-
lites, high throughput, and non-destructive sample treatment22. Although NMR-based metabolomics approach 
has many of these advantages, its usage in CRC has been limited; and only two NMR-metabolomics studies on 
CRC have recently been reported23,24.
Dykstra et al.23 conducted NMR-based urine metabolomics studies on CRC, but their research was focused on 
adverse events and responsiveness to chemotherapy in stage III and IV patients, search for personalized therapies. 
Wang et al.24 analyzed and compared urinary metabolic profile differences between early stage CRC (stages I and II) 
and healthy controls using an NMR-based metabolomics approach. The major finding of this research was the 
identification of stage I and II specific biomarkers indicating that several metabolisms including those from 
amino acids, glycolysis, the TCA cycle, the urea cycle, choline metabolism, and gut microflora metabolism were 
highly active in these stages.
It is widely accepted that most CRCs develop following the adenoma-carcinoma sequence, in which normal 
colorectal epithelium is transformed into benign neoplasm (adenoma) and, subsequently, into malignant neo-
plasm (invasive carcinoma) as a result of the accumulation of multiple genetic and epigenetic mutations. This 
implies that mutated genes, activated molecular pathways and, subsequently accumulated metabolites will be 
different at each stage of the adenoma-carcinoma sequence.
Here, we investigate the differences in the urine metabolic profiles of patients with colorectal neoplasia (CRN) 
including CRC and precancerous lesions, and healthy volunteers using an NMR-based urine metabolomics 
approach. In addition, we evaluate the applicability of this approach as a high sensitivity and specificity diagnostic 
tool especially for early detection of precancerous colorectal lesions.
Results
participant characteristics. The characteristics of both patients and healthy controls are summarized in 
Table 1. The median age of patients with CRN (60 years; range 32–85) was older than that of healthy controls (52 
years; range 22–76), and there were more males in the CRN group than in the control group (67.4% vs. 48.7%). 
Body mass indexes (BMI) of patients with CRN (23.56 kg/m2 in average; range 18.3–33.4) were slightly higher 
than those from healthy controls (23.0 kg/m2 in average; range 16.9–34.6). After patients underwent endoscopic 
resection or surgical resection for CRN; advanced adenoma was diagnosed in 36 patients; stage 0 CRC, in 24 
patients; stage I CRC, in 8 patients; stage II CRC, in 7 patients; stage III CRC, in 13 patients; and stage IV CRC, 
in 4 patients. Cancers were classified according to the 7th edition of the American joint Committee on Cancer 
(AJCC) cancer staging manual25.
CEA and CA 19-9 levels for patients with stage I to IV CRC and for healthy controls were also assessed. 
Among patients with stage I to IV CRC, the level of CEA and CA 19-9 increased only in 2 individuals from each 
group. Therefore, the sensitivity and specificity of CEA and CA 19-9 were 6.2% and 99.3%, respectively.
Discrimination and diagnosis of CRN and healthy control groups. We analyzed all the NMR 
spectroscopy-based urine metabolic profiles and performed multivariate statistical analyses to discriminate 
between CRN patients and healthy controls. OPLS-DA was applied to our data because it can discriminate 
between groups even in the presence of high structured noise or confounding factors. As indicated in Fig. 1a, 
the OPLS-DA score plot was created using one predictive (Pp) and three orthogonal components (P0); it shows a 
significant discrimination between the CRN and the healthy control groups with an R2 value (overall goodness 
of fit) of 0.864 and a Q2 value (overall cross-validation coefficient) of 0.714 (Table 2). The prediction model was 
built using the same number of predictive and orthogonal components as in the OPLS-DA score plot, after deter-
mining an a priori cut-off value of 0.5, resulting in 96.2% specificity and 100% sensitivity for pre-invasive CRN 
diagnosis (Fig. 1b and Table 2).
early stage CRN diagnosis. For the CRN diagnosis, we used patient samples from all CRC stages including 
advanced adenoma and stage 0 to IV CRCs; discrimination between CRN and healthy control groups is shown 
as two different data concentration groups in the plot (Fig. 1a). As the majority of CRN patients were diagnosed 
as very early CRC stages including advanced adenoma (n = 36) and stage 0 CRC (n = 24), our results suggest that 
this approach would be effective on early stage diagnosis. Therefore, we moved onto earlier stage diagnosis using 
only advanced adenoma and stage 0 patient samples. When advanced adenoma and stage 0 CRC were grouped 
as pre-invasive CRN, which is an indication of endoscopic resection as first-line therapy, the OPLS-DA score plot 
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revealed statistically significant discrimination between pre-invasive CRN and healthy control groups (Fig. 1c), 
and presented similar sensitivity and specificity for diagnosing pre-invasive CRN of 96.2% and 95%, respectively 
(Fig. 1d and Table 2). When stage 0 CRC (Fig. 1e) and advanced adenoma (Fig. 1f) were analyzed independently, 
they were statistically well discriminated from the healthy control group with over 75% sensitivity and over 98% 
specificity. According to the cross-validation function of the SIMCA-P software, we obtained reasonable R2 and 
Q2 values over 0.72 and over 0.63, respectively. Diagnostic analysis results are presented in Table 2.
Metabolic differences between colorectal neoplastic lesions and healthy controls. Major con-
tributing metabolites for group separation were identified by statistical total correlation spectroscopy (S-TOCSY; 
Fig. 2). Representative metabolites were slightly different according to each CRC stage analyzed; also relative 
amounts of taurine, alanine, 3-aminoisobutyrate, and valine were greater in CRN samples than in healthy con-
trols, where relative amounts of threonine, glycerol, hippurate, ascorbate, creatinine and citrate were greater in 
healthy controls than in CRN groups (Tables 3 and 4). To evaluate the importance of discriminating metabolites, 
the receiver operating characteristic (ROC) curve analysis was applied to our data. Predicted importance by the 
OPLS-DA model showed that the areas under the curve (AUCs) were 0.823 for taurine, 0.783 for alanine and 
0.842 for 3-aminoisobutyrate (Fig. 3a). In multiple ROC analyses, several metabolites including taurine, glycerol, 
alanine and 3-aminoisobutyrate were implicated as good discriminators for CRN patients (Fig. 3b). However, we 
excluded glycerol as a concerning metabolite, although it seemed as a secondly important metabolite in multiple 
ROC analysis, because of its poor AUC value (Fig. 3c).
Diagnostic accuracy of the study. Although the population used in our discrimination models have low 
prevalence, varying from 11.9 to 36.6%, most of their sensitivities and specificities were over 95%, except for the 
advanced adenoma population which had a 75% sensitivity (Table 5). However, sensitivity and specificity do not 
provide information about the probability of a test26,27. Therefore, we also calculated the predictive values and 
likelihood ratio (LR) from our data. Interestingly, the positive predictive values (PPVs), as well as the negative 
predictive values (NPVs) presented high scores, over 87.6% and up to 100% for different patients’ cancer stages 
and prevalence. Moreover, when the LR values are >10 and <0.1, it means that there is strong evidence to rule in 
or rule out diagnosis in most circumstances28; our diagnostic results showed LR values >25 and <0.05 which are 
in close correspondence with this rationale. Diagnostic accuracy parameters are summarized in Table 5.
Discussion
The metabolomics approach for the discrimination and diagnosis of CRC patients has been applied to a variety of 
human samples. The majority of those studies used either tissue or blood samples, but only a few involved feces or 
fecal water extractions. Wang et al.19 reported metabolomics profiling of tissue samples, using in 1H NMR, from a 
large cohort of rectal cancer patients and healthy controls. The authors made an excellent separation and demon-
strated the existence of distinguishing metabolites among different stages of rectal cancer tissues and healthy 
controls. Another group analyzed metabolites in intact tumor samples and samples of adjacent mucosa obtained 
from 26 patients undergoing surgical resection for CRC using high-resolution magic angle spinning NMR20.
They reported that tumor-adjacent mucosa (10 cm from tumor margin) harbors unique metabolic field 
changes that distinguish tumors according to T- and N-stage with a high predictive capability, as good as tumor 
tissue itself.
Although metabolomics profiling using tissue samples provides good discrimination between CRC and 
healthy controls, it is difficult to use as a screening test for early detection of CRC because the test sample is 
usually obtained by invasive methods. Therefore, searching for useful and easy to obtain test samples, several 
Patients with colorectal 
neoplasiaa (n = 92)
Healthy controls 
(n = 156)
Age (years), median (range) 60(32–85) 52(22–76)
Gender, male (%) 62(67.4%) 76(48.7%)
BMI(kg/m2), median (range) 23.56 (18.3–33.4) 23.0(16.9–34.6)








Serum tumor marker (>cut off valued/totale)
      CEA 2/32 1/156
      CA 19-9 2/32 1/156
Table 1. Characteristics of patients and healthy controls. aColorectal neoplasia, including colorectal cancer and 
advanced adenoma. bCRC, colorectal cancer. cTNM stage, classified according to the American Joint Committee 
on Cancer (AJCC) 7th edition. dCut off value of CEA, 5 ng/ml; Cut off value of CA19-9, 37 U/ml. eTotal number 
of patients with stage I to 4 CRC (n = 32 patients).
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researchers analyzed the serum or fecal metabolomics profiles from CRC patients. In one study, the metabolomics 
approach was used to search for potential diagnostic biomarkers in the serum of 30 patients surgically treated 
for CRC21. Of all the analyzed metabolites, the concentrations of only 6 were significantly increased or decreased 
Figure 1. OPLS-DA score plots and prediction models for colorectal neoplasia and healthy controls. Models 
were obtained using one predictive (Pp) and three orthogonal components (P0). The OPLS-DA models show 
good separation between (a) healthy controls vs. all colorectal neoplasia, (b) healthy controls vs. pre-invasive 
colorectal neoplasia, including advance adenoma and stage 0 CRC, (c) healthy controls vs. stage 0 CRC, and 
(d) healthy controls vs. advanced adenoma, (e) stage 0 CRC, and (f) advanced adenoma. The prediction model 
validation by three-fold cross-validation was based on the OPLS-DA (b,d). An a priori cut-off value of 0.5 was 
used to determine the prediction result. Black boxes: healthy control group; Red triangles: colorectal neoplasia 
group; Open triangles: unknown samples.
Healthy control (n = 156) CRNa (n = 92)
Model R2/Q2 Specificity SensitivityModel Validation Model Validation
All CRN*
Samples 104 52 62 30 R2 0.864
96.2% 100%
Prediction 50/52 30/30 Q2 0.714
Pre-invasive CRNb
Samples 104 52 40 20 R2 0.845
96.2% 95%
Prediction 50/52 19/20 Q2 0.732
Stage 0 CRCc
Samples 104 52 17 7 R2 0.830
98.1% 100%
Prediction 51/52 7/7 Q2 0.644
Advanced adenoma
Samples 104 52 24 12 R2 0.727
100% 75%
Prediction 52/52 9/12 Q2 0.634
Table 2. Diagnostic analysis of the urine-NMR metabolomics samples in detecting colorectal neoplasia. aCRN, 
colorectal neoplasia including colorectal cancer and advanced adenoma. bPre-invasive CRN, stage 0 colorectal 
cancer and advanced adenoma. cCRC, Colorectal cancer.
5Scientific RepoRts |          (2019) 9:4786  | https://doi.org/10.1038/s41598-019-41216-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
compared to those from control samples. Supervised predictive models allowed a separation of 93.5% of CRC 
patients from healthy controls using these metabolites. However, they were not able to classify and analyze the 
results according to CRC stages.
NMR was also used to profile the serum metabolome in metastatic CRC (mCRC) patients and to determine 
whether a disease signature is predictive of overall survival (OS)22. In the training set, NMR metabolomics pro-
filing was able to discriminate patients with mCRC with a cross-validated accuracy of 100%. Also, patients with 
short or long OS could be identified by proton NMR (1H-NMR) profiling with an accuracy of 78.5%. Lin et al. 
determined fecal metabolites of 68 CRC patients (Stage I/II = 20, Stage III = 25, and Stage IV = 23) and 32 healthy 
controls using 1H NMR, establishing the differences between the CRC stages. They reported that even early CRC 
stages (stage I/II) were clearly distinguished from healthy controls based on their metabolomics profiles23. These 
results showed the potential utility of metabolomics as a diagnostic marker in CRC. However, more data are 
needed for fecal metabolomics profiling before this approach can be adopted with confidence. Especially, there is 
a lack of data about advanced adenoma or stage 0 CRC which is an indication of less invasive endoscopic treat-
ment. Furthermore, although obtaining fecal samples is non-invasive, it is a less pleasant experience compared 
with urine collection.
Figure 2. Identification of metabolites contributing to colorectal neoplasia (CRN). Variable contributions from 
statistical total correlation spectroscopy (S-TOCSY) show the model coefficients for each NMR variable. (a) 
Healthy controls vs. all colorectal neoplasia, (b) Healthy controls vs. pre-invasive colorectal neoplasia including 
advance adenoma and stage 0 CRC, (c) Healthy controls vs. stage 0 CRC, and (d) Healthy controls vs. advanced 
adenoma. The color scale based on the value of P(coor)p, according to weight is used as a discriminator 
between two groups. Pp represents the modeled covariant. Signals, color coded metabolites, that significantly 
discriminate between the two groups were annotated on the model coefficient plot.
Healthy control
All stage












Table 3. Representative markers according to CRN stages.
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Recently, several NMR-based urine metabolomics studies have been reported for CRC. One of these studies 
only analyzed samples from patients with stage III and IV CRC to investigate adverse events and responsiveness 
to chemotherapy23. In contrast, the purpose of our study is to develop a diagnostic tool using an NMR-based urine 
metabolomics approach based on a better understanding of the metabolic profile of patients with early CRC. The 
purpose of Dykstra’s research is much related to the development of a personalized medicine treatment based on 
no Metabolites Chemical shift (ppm) p-value Changes
1 3-Aminoisobutyrate 1.18(d) 5.83 × 10−06 ▲
2 Alanine 1.48(d), 1.21 × 10−03 ▲
3 Ascorbate 3.75(m), 4.53(m) 6.81 × 10−10 ▽
4 Citrate 2.54(d), 2.71(d) 3.66 × 10−05 ▽
5 Creatinine 3.05(s), 4.07(s) 1.30 × 10−2 ▽
6 Glycerol 3.58(m), 3.66(m), 3.78(m), 5.22 × 10−32 ▽
7 Hippurate 3.98(d), 7.56(t), 7.64(t), 7.83(m) 4.53 × 10−04 ▽
8 Taurine 3.27(t), 3.45(t) 2.86 × 10−04 ▲
9 Threonine 1.31(d), 3.58(d) 7.03 × 10−03 ▽
10 Urea 5.80(s) 7.26 × 10−04 ▲
11 Valine 0.99(d) 8.35 × 10−07 ▲
Table 4. Marker identification for early detection of colorectal neoplasia.
Figure 3. ROC analysis of contributing metabolites for discrimination. (a) OPLS-DA based ROC curve 
analysis for diagnosis of pre-invasive colorectal neoplasia (CRN). Taurine, alanine, 3-aminoisobutyrate showed 
very high AUC scores. (b) Multiple ROC curve analysis for 11 metabolites contributing for discrimination. The 
color scale on the right shows whether each metabolite concentration level was increased or decreased in CRN. 
(c) ROC curves of glycerol showing high ranking on the multiple ROC curve analysis, but poor sensitivity and 
specificity.
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metabolic profiles, rather than to the development of diagnostic methods for early CRC patients. Therefore, it has 
a different character from the final goal we pursue in this study.
In other urinary metabolomics study that used samples from 20 CRC patients and 14 healthy controls, a 
panel of metabolic markers composed of citrate, hippurate, p-cresol, 2-aminobutyrate, myristate, putrescine, and 
kynurenate was able to discriminate CRC subjects from their healthy counterparts15. However, the early stage 
CRC (stages I and II) group comprised only 8 patients, and none had precancerous lesions. From our perspec-
tive, the most recent research conducted by Wang et al.24 is particularly interesting and relevant to our study as it 
analyzed samples from early I/II CRC patients. They showed urinary metabolic differences between early stage 
colorectal cancer and healthy controls and provided 16 potential CRC biomarkers related to several key metabolic 
pathways.
In contrast, the present study contains more than 65% early stage CRN patients, including 39% with advanced 
adenoma (n = 36) and 26% with stage 0 CRC (n = 24). Since CRC is slowly aggravated by adenoma-carcinoma 
sequence for a long time, early diagnosis is essential to elevate the survival rate and to ease the treatment for the 
patients29. Therefore, this study, which analyzes patients at an earlier stage CRC than previous studies, will be 
highly valuable for the clinic; it presents strong data indicating the potential of urine metabolomics as a screening 
tool for early stage CRC.
To date, our study is the first and the largest NMR-based urine metabolomics study of CRN patients including 
precancerous lesions such as advanced adenomas and stage 0 CRC. For developing a diagnostic model, the sample 
type and the way it is collected are very important for the patient, both convenience and preference. In this regard, 
even though urine is a very attractive biofluid for clinical purposes, including diagnosis or prognosis prediction, it 
has not been used often for CRC metabolomics studies. This is reflected in a relative scarcity of evidence of change 
in urine metabolites in CRC. However, more than 300 metabolites are detectable in urine and their concentration 
levels may be used as signature of systemic diseases.
Our current study shows that urine metabolomics has potential for CRN diagnosis with extremely high sensi-
tivity and specificity. Surprisingly, our results also show a strong diagnostic power for patients with precancerous 
lesions and early stage CRN. Additionally, the statistical parameters showed highly reliable R2 and Q2 values, 
over 0.72 and over 0.63, respectively. A large discrepancy between R2 and Q2 value indicates an overfitting of the 
model, but our diagnostic result presented theoretically ideal R2 and Q2 values30. According to the SIMCA users’ 
guide, the Q2 value is an estimate of the predictive ability of the model, calculated by cross-validation, and a Q2 
value over 0.65 together with an R2 value over 0.78 would be indicative of a good model31.
Although sensitivity and specificity are widely used diagnostic accuracy parameters, their high dependence on 
prevalence is a well known limitation32. Therefore, the use of predictive value and likelihood ratio reflecting the 
prevalence is very important to overcome these vulnerabilities33. The PPV represents the probability of having the 
disease after a positive test result, whereas the NPV is the probability of not having the disease after a negative test 
result34,35. However, the predictive values have one critical limitation; they could only be applied when the clinical 
prevalence is identical. So, the use of an alternative diagnostic parameter, less dependent on the prevalence, is 
necessary; thus we adopted the LR, a combination of sensitivity and specificity. The LR can be used in conjunction 
with disease prevalence to estimate an individual patient’s probability of having a disease31,32. In other words, the 
LR is less dependent on the prevalence because it has the advantage of giving equal weights to the sensitivity and 
specificity. Our diagnostic results showed ideal LR points.
CRC is a common malignant tumor and has become a major public health concern. Despite improved treat-
ment approaches done over the past decade, the outcomes or survival of patients with advanced disease have 
remained depressingly poor, and treatment costs have increased24. CRC is sporadic in 90% of patients and most 
CRC cases develop from a preclinical benign precursor, adenoma to invasive cancer over the span of years. The 
characteristics of CRC including high incidence, protracted and treatable preclinical phase, high cost of treatment 
and correlation of mortality with disease stage are well-suit for population screening24,25. FOBT is a well-known 
CRC screening method. The advantages of this method when compared for example with colonoscopy are its 
simplicity and cost-effectiveness. However, the sensitivity of FOBT is low and its validity remains debatable. 
Also, it has been demonstrated that the highest validity rate is needed for successful CRC screening26. The pur-
pose of screening strategies is to save cost through early disease detection and treatment. Therefore, screening 
test for CRC must be able to detect adenoma or early stage CRC. For this reason, out finding is important and 
meaningful.
In this study, we identified several metabolites useful as CRN discrimination factors including taurine, ala-
nine, 3-aminoisobutyrate (BAIB), valine, threonine, glycerol, hippurate, ascorbate, creatinine and citrate. Multiple 
ROC curve analyses were performed to evaluate the importance of discriminating metabolites; we chose tau-
rine, alanine, and BAIB as key contributing metabolic markers based on them. Although glycerol presented as 
Prevalence Sensitivity Specificity PPVa NPVb (+) LRc (−) LRd
All CRN 36.6% 100% 96.2% 93.8% 100% 26.0 0.00
Pre-invasive CRN 27.8% 95% 96.2% 90.5% 98.0% 24.7 0.05
Stage 0 CRN 11.9% 100% 98.1% 87.6% 100% 52.0 0.00
Advanced adenoma 18.8% 75% 100% 100% 94.6% N/A 0.25
Table 5. Diagnostic accuracy values. aPPV, positive predictive value; (sensitivity * prevalence)/[sensitivity 
* prevalence + (1 − specificity) * (1 − prevalence)]. bNPV, negative predictive value; [specificity * 
(1 − prevalence)]/[(1 − sensitivity) * prevalence + specificity * (1 − prevalence)]. c(+) LR, positive Likelihood 
Ratio; sensitivity/(1 − specificity). d(−) LR, negative Likelihood Ratio; (1 − sensitivity)/specificity.
8Scientific RepoRts |          (2019) 9:4786  | https://doi.org/10.1038/s41598-019-41216-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
a secondly important metabolite from multiple ROC analyses, its poor AUC value of 0.679 is a critical reason to 
exclude it from the key marker selection. Interestingly, the three selected metabolites are similar in structure and 
correlated with metabolic pathways. BAIB homeostasis could also be correlated with congenital abnormality of 
the colorectal systems, and its concentration level is increased in gastric cancer tissues27,28. Still, direct evidence 
is lacking concerning the role of BAIB in various cancers. However, several reports have indicated that BAIB has 
important effects on energy metabolism including pyrimidine metabolism, beta oxidation, and glucose home-
ostasis. Cancer cells need and consume excessive energy for their fast and aggressive growth and metastasis, 
so energy supplementation must be completed in any way. We suggest that the identified CRC representative 
metabolites taurine, alanine, and BAIB could be part of the energy supplementation intermediates. Taurine and 
alanine could be energy sources by themselves, whereas BAIB might control energy metabolism, which should 
be upregulated in cancer patients.
Current NMR-based urine metabolomics results showed high sensitivities and specificities for discriminating 
colorectal neoplasia.
Interestingly, regardless of low prevalence, all diagnostic parameters including sensitivity, specificity, predic-
tive value, and likelihood ratio are good enough represented.
In conclusion, NMR-based untargeted urine metabolomics approach significantly differentiates between 
patients with CRN and healthy controls. Our results also indicated that urinary metabolic profiles have strong 
potential as screening tools for accurate diagnosis of pre-invasive CRN.
Methods
participants. A total of 92 patients with CRN including CRC or advanced adenoma were enrolled from July 
2013 to April 2016. They underwent endoscopic resection or surgical resection for CRN. In this study, advanced 
adenoma was defined tubular adenoma, tubulovillous adenoma, villous adenoma or serrated adenoma with a size 
≥1 cm. Stages 0 to IV CRC were determined according to the American joint Committee on Cancer (AJCC) 7th 
edition. Stage 0 CRC was defined either as cancer cells confined within the intraepithelial or mucosal lamina pro-
pria with no extension into submucosa, or adenoma demonstrating a high grade dysplasia. Advanced adenoma 
and stage 0 CRC were grouped as pre-invasive CRN.
The healthy control group (normal) comprised 156 healthy subjects who underwent health screening. Healthy 
controls had no detected abnormalities, neither in blood tests, nor in endoscopic examination, diagnostic imag-
ing, nor medical interview.
Patients with prior treatment including chemotherapy or surgery, serious complications including active 
bleeding or obstruction, decompensated liver cirrhosis, active hepatitis, collagen disease, severe uncontrolled 
diabetes mellitus (HbA1c > 7.5%), chronic renal failure (glomerular filtration rate <30 ml/min/1.73 m2 or on 
dialysis), and pre-existing carcinoma at other sites were excluded.
This study was approved by the institutional review board of Samsung Medical Center. All the treatment 
methods were carried out in accordance with the approved guideline. Informed consent was obtained from all 
participants.
sample collection, preparation and NMR experiments. The first morning urine samples (3 to 5mL) 
were collected and centrifuged at 3000 rpm for 15 minutes at 4 °C. Supernatants were transferred to frozen tubes 
and stored at –80 °C until processing. Frozen urine samples were thawed at room temperature and immediately 
centrifuged at 15,000 rpm at 4 °C for 20 min. After centrifugation, 50 µL of phosphate buffer (1.5 M K2HPO4 + 1.5 
Na2HPO4, pH 7.4) were added to 500 µL of supernatant and incubated at room temperature for 10 min. Incubated 
mixtures were centrifuged before 450 µL of supernatant were blended together with a 50 µL 0.25% trimethylsi-
lanepropionic acid (TSP) solution in deuterium oxide. Finally, the whole 500 µL of this mixture were transferred 
to a 5 mm standard NMR tube. All the proton NMR spectra were acquired using a 500 MHz NMR spectrometer 
(Bruker Biospin, Avance 500, Billerica, MA, USA). Experimental parameters and data acquisition processes were 
basically similar to those previously reported29.
Data processing and statistical analysis. Proton NMR spectral data were manually processed by 
Fourier transformation, phase correction, baseline correction, referencing, and normalized against the internal 
standard 0.025% TSP signal. All processed data were binned to a 0.0092 ppm width by an in-house Perl script, 
except for the water signal region (4.6–5.2 ppm), and numerically transformed. Transformed data were analyzed 
with statistical software including SIMCA-P version 11.0 (Umetrics, Umeå, Sweden), OrigionPro 8 (OriginLab 
Corporation, Northampton, MA, USA), and R (The R Foundation for Statistical Computing, Vienna, Austria). 
For statistical analysis, all the imported data were normalized as mean-centered scaling using the Pareto scaling 
algorithm in SIMCA-P software. Healthy control and colorectal neoplastic lesion groups were statistically dis-
criminated using orthogonal projections to latent structure discriminant analysis (OPLS-DA).
Metabolites identification and representative marker selection. For the representative metabolites 
identification, all proton NMR signals were referenced against an internal standard TSP signal and identified 
using the Chenomx NMR database (Spectral Database, Edmonton, Alberta, Canada). In brief, all the experi-
mental proton NMR signals from patients were fit into the Chenomx database by shifting under appropriate pH 
ranges. Identified metabolites were exported as numeric values and the area under curve (AUC) was analyzed 
using an open source receiver operating characteristics (ROC) curve analysis tool30.
Validation of prediction models for different stages. The class prediction model was validated as pre-
viously described31. Briefly, one-third of the samples of each group (52 healthy control and 30 CRN samples) were 
9Scientific RepoRts |          (2019) 9:4786  | https://doi.org/10.1038/s41598-019-41216-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
blinded without any group information and the rest of the samples (104 healthy control and 62 CRN samples) 
were used for prediction model construction; 0.5 was used as an a priori cut-off value for evaluating the prediction 
model32, and the sensitivity and specificity were calculated. Positive predictive values (PPVs) were calculated by 
the following formula: (sensitivity * prevalence)/[sensitivity * prevalence + (1 − specificity) * (1 − prevalence)]; 
while negative predictive values (NPVs) were calculated by: [specificity * (1 − prevalence)]/[(1 − sensitivity) * 
prevalence + specificity * (1 − prevalence)]; positive likelihood ratio (+LR), by: sensitivity/(1 − specificity); and 
negative likelihood ratio (-LR), by: (1 − sensitivity)/specificity. The same approach was applied to pre-invasive 
CRN prediction validation.
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